Clinical Trials Logo

Liver Metastases clinical trials

View clinical trials related to Liver Metastases.

Filter by:

NCT ID: NCT04683783 Completed - Rectal Cancer Clinical Trials

National Registry of Liver First Approach

RENACI
Start date: June 1, 2019
Phase:
Study type: Observational [Patient Registry]

Liver metastases are present in 15-25% of patients with colorectal cancer at the time of diagnosis of the primary tumor, which is defined as synchronous liver metastases. Treatment for the potential cure of this disease includes surgical resection of both the primary tumor and liver metastases. The liver first approach was described by Mentha for patients with asymptomatic rectal tumors with with initially unresectable or borderline resectable liver metastases. There is little data in the scientific literature on how many patients scheduled for this strategy complete both surgeries and/or undergo the full chemo/radiation therapy.

NCT ID: NCT04676633 Completed - Clinical trials for Hepatocellular Carcinoma

Safety, Tolerability, PK, Anti-Tumor Activity of STP705 in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy

Start date: March 1, 2021
Phase: Phase 1
Study type: Interventional

This is an open label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of STP705 administered intratumorally in cholangiocarcinoma, hepatocellular carcinoma or liver metastasis in subjects with advanced/metastatic or surgically unresectable solid tumors who are refractory to standard therapy. Goals: 1. To determine the MTD or RP2D of STP705 when administered intratumorally into cholangiocarcinoma, hepatocellular carcinoma, or liver metastasis. 2. To establish the dose of STP705 recommended for future phase 2 studies when administered intratumorally.

NCT ID: NCT04509492 Completed - Clinical trials for Pancreatic Neoplasms

Role of EUS in Detection of Liver Metastasis

Start date: October 1, 2020
Phase:
Study type: Observational

Liver metastasis may not be detected by CT and MRI due to their small size while they can be detected by EUS. Also, EUS-FNA has a great impact in improving the diagnostic accuracy of EUS. Objectives: To assess the feasibility of EUS in the detection of occult small hepatic focal lesions at the time of primary tumor staging, not seen by CT or MRI.

NCT ID: NCT04338685 Completed - Clinical trials for Carcinoma, Hepatocellular

A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases

Start date: July 16, 2020
Phase: Phase 1
Study type: Interventional

Phase I study of RO7119929 given orally to participants with unresectable advanced or metastatic primary liver cancers and other solid tumors with predominant liver involvement. The primary objective of the study is to explore the safety and to determine the maximum tolerated dose (MTD) and/or optimal biologic dose (OBD) of RO7119929 as single agent.

NCT ID: NCT04269499 Completed - Liver Cancer Clinical Trials

Real-time Imaging of Holmium Radioembolization: a Feasibility Study

Emeritus
Start date: November 11, 2019
Phase: N/A
Study type: Interventional

This is a feasibility study in which patients with liver tumors are treated with holmium radioembolization under real time MR imaging.

NCT ID: NCT03888638 Completed - Colorectal Cancer Clinical Trials

The Role of Tumor-associated Macrophages in Colorectal Liver Metastases

Start date: January 1, 2015
Phase:
Study type: Observational

Colorectal cancer is a major cause of mortality worldwide. Most patients develop colorectal liver metastases (CLM), and for such patients hepatectomy combined with chemotherapy may be curative. Nevertheless, in the era of precision medicine there is a critical need of prognostic markers to cope with the heterogeneity of CLM patients. Tumor-associated macrophages (TAMs) pave the way to tissue invasion and intravasation providing a nurturing microenvironment formetastases. The quantification of immune landscape of tumors has provided novel prognostic indicators of cancer progression, and the quantification of TAMs might explain the heterogeneity of CLM patients. Here, we will investigate the development of a new diagnostic tool based on TAMs with the aim to define the causative role of TAMs in CLM patients. This will open new clinical scenarios both for the diagnosis, therapy and prognosis, leading to the refinement of the therapeutic output in a personalized medicine perspective.

NCT ID: NCT03757858 Completed - Cancer Clinical Trials

Hyperthermia Combined With Immunotherapy in the Treatment of Abdominal and Pelvic Malignancies or Metastases

Start date: March 1, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

It is a non-randomized pilot study.The allocation will be determined by patients or their immediate family members who were cooperative with physician's interpretations on the disease progression and updated information of cutting of edge treatment, the financial affordability, availability of treatment plans, possible tolerance or risks etc.The purpose of this study is to investigate the clinical efficacy and toxicity of autologous cellular immunotherapy combined with hyperthermia in abdominal and pelvic malignancies or metastases patients. Furthermore, to characterize response to different regimens,the investigators intent to explore the predictive and prognostic biomarker, as well as the changes in immune repertoire.

NCT ID: NCT03741088 Completed - Clinical trials for Carcinoma, Hepatocellular

Study to Evaluate VORTX Rx (Theresa)

Theresa
Start date: March 21, 2018
Phase: N/A
Study type: Interventional

Multi-center, Open-labeled, Non-randomized Study to Evaluate the Acute Technical Performance and Safety Profile of the VORTX Rx® for Ablation of Primary and Metastatic Liver Tumors

NCT ID: NCT03590119 Completed - Clinical trials for Neuroendocrine Tumors

Intra-arterial Lutetium-177-dotatate for Treatment of Patients With Neuro-endocrine Tumor Liver Metastases

LUTIA
Start date: August 1, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

The objective is to investigate the impact of intra-arterial administration of 177Lu-dotatate on the intrahepatic biodistribution in patients with NET liver metastases. Our primary objective is to evaluate if there is a difference in post-treatment tumor-to-non-tumor (T/N) activity concentration ratio on SPECT/CT between the intra-arterial treated liver lobe and the intravenous treated liver lobe.

NCT ID: NCT03518632 Completed - Liver Metastases Clinical Trials

Preoperative Physical Activity Intervention in Patients Before Planned Liver Resection for Cancer (APACHE)

APACHE
Start date: March 27, 2018
Phase: N/A
Study type: Interventional

The aim of this study is to assess the impact of preoperative physical activity on physical capacities of patients undergoing liver resection for primary or secondary liver cancer.